FindTrial
Sign In

Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

Comparative Study Between the Efficacy of Oral Gemifloxacin and Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04168099
Enrollment
60
Registered
2019-11-19
Start date
2018-12-01
Completion date
2028-12-30
Last updated
2019-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous Bacterial Peritonitis

Brief summary

oral Gemifloxacin versus intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Detailed description

Comparative Study between the Efficacy of oral Gemifloxacin and intravenous Cefotaxime in treatment of spontaneous bacterial peritonitis

Interventions

DRUGCefotaxime

Cefotaxime IV

DRUGGemifloxacin

Gemifloxacin oral

Sponsors

Tanta University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with spontaneous bacterial peritonitis

Exclusion criteria

* secondary peritonitis

Design outcomes

Primary

MeasureTime frameDescription
Number of patients with resolution of infection6 monthsthe total number of patients with resolution of infection

Countries

Egypt

Contacts

Primary ContactSherief Abd-Elsalam, ass. prof.
sheriefabdelsalam@yahoo.com00201147773440
Backup Contactsherief abd-elsalam, ass. prof.
sherif_tropical@yahoo.com00201147773440

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026